Literature DB >> 21740581

Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.

Cornelis J M Melief1, John J O'Shea, David F Stroncek.   

Abstract

The field of cellular therapy of cancer is moving quickly and the issues involved with its advancement are complex and wide ranging. The growing clinical applications and success of adoptive cellular therapy of cancer has been due to the rapid evolution of immunology, cancer biology, gene therapy and stem cell biology and the translation of advances in these fields from the research laboratory to the clinic. The continued development of this field is dependent on the exchange of ideas across these diverse disciplines, the testing of new ideas in the research laboratory and in animal models, the development of new cellular therapies and GMP methods to produce these therapies, and the testing of new adoptive cell therapies in clinical trials. The Summit on Cell Therapy for Cancer to held on November 1 and 2, 2011 at the National Institutes of Health (NIH) campus will include a mix of perspectives, concepts and ideas related to adoptive cellular therapy that are not normally presented together at any single meeting. This novel assembly will generate new ideas and new collaborations and possibly increase the rate of advancement of this field.

Entities:  

Mesh:

Year:  2011        PMID: 21740581      PMCID: PMC3160382          DOI: 10.1186/1479-5876-9-107

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  36 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 2.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 3.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

4.  Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Authors:  Michal J Besser; Ronnie Shapira-Frommer; Avraham J Treves; Dov Zippel; Orit Itzhaki; Liat Hershkovitz; Daphna Levy; Adva Kubi; Einat Hovav; Natalia Chermoshniuk; Bruria Shalmon; Izhar Hardan; Raphael Catane; Gal Markel; Sara Apter; Alon Ben-Nun; Iryna Kuchuk; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

5.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Authors:  Andreas Mackensen; Norbert Meidenbauer; Sandra Vogl; Monika Laumer; Jana Berger; Reinhard Andreesen
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

7.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Farah Essahsah; Lorraine M Fathers; Rienk Offringa; Jan Wouter Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

8.  Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

Authors:  Amir Khammari; Nathalie Labarrière; Virginie Vignard; Jean-Michel Nguyen; Marie-Christine Pandolfino; Anne C Knol; Gaëlle Quéreux; Soraya Saiagh; Anabelle Brocard; Francine Jotereau; Brigitte Dreno
Journal:  J Invest Dermatol       Date:  2009-06-25       Impact factor: 8.551

9.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Authors:  Maria Berg; Andreas Lundqvist; Philip McCoy; Leigh Samsel; Yong Fan; Abdul Tawab; Richard Childs
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

10.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Authors:  Catherine M Bollard; Stephen Gottschalk; Ann M Leen; Heidi Weiss; Karin C Straathof; George Carrum; Mariam Khalil; Meng-fen Wu; M Helen Huls; Chung-Che Chang; M Victoria Gresik; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2007-07-03       Impact factor: 22.113

View more
  1 in total

Review 1.  Cationic liposome/DNA complexes: from structure to interactions with cellular membranes.

Authors:  Giulio Caracciolo; Heinz Amenitsch
Journal:  Eur Biophys J       Date:  2012-06-19       Impact factor: 1.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.